LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Начало・Списък с акции・Altimmune Inc

Altimmune Inc

Затворен

3.4 -3.41

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.36

Максимум

3.52

Ключови измерители
By Trading Economics
Приходи	-8.3M -27M
Продажби	21K 26K
Марж на печалбата	-105,223.077
Служители	57
EBITDA	-10M -29M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+290.93% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-68M 453M
Предишно отваряне	6.81
Предишно затваряне	3.4

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

5.365 / 6.0486 Подкрепа & съпротива

Altimmune Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.03.2026 г., 22:51 ч. UTC

Печалби

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18.03.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18.03.2026 г., 20:31 ч. UTC

Печалби

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18.03.2026 г., 23:31 ч. UTC

Пазарно говорене

Gold Rises on Likely Technical Recovery -- Market Talk

18.03.2026 г., 22:49 ч. UTC

Пазарно говорене

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18.03.2026 г., 22:41 ч. UTC

Пазарно говорене

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18.03.2026 г., 22:36 ч. UTC

Печалби

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18.03.2026 г., 22:24 ч. UTC

Печалби

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18.03.2026 г., 22:23 ч. UTC

Печалби

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18.03.2026 г., 22:23 ч. UTC

Печалби

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18.03.2026 г., 21:58 ч. UTC

Печалби

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18.03.2026 г., 21:55 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

18.03.2026 г., 21:55 ч. UTC

Пазарно говорене

Печалби

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18.03.2026 г., 21:40 ч. UTC

Пазарно говорене

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18.03.2026 г., 21:16 ч. UTC

Пазарно говорене

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18.03.2026 г., 21:00 ч. UTC

Значими събития в новините

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18.03.2026 г., 20:58 ч. UTC

Печалби

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18.03.2026 г., 20:41 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:29 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:25 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:17 ч. UTC

Печалби

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18.03.2026 г., 20:14 ч. UTC

Пазарно говорене

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18.03.2026 г., 20:09 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18.03.2026 г., 20:07 ч. UTC

Печалби

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18.03.2026 г., 20:06 ч. UTC

Печалби

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology Sees 3Q Gross Margin About 81% >MU

18.03.2026 г., 20:03 ч. UTC

Печалби

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Сравнение с други в отрасъла

Ценова промяна

Altimmune Inc Прогноза

Ценова цел

By TipRanks

290.93% нагоре

12-месечна прогноза

Среден 13.8 USD 290.93%

Висок 25 USD

Нисък 4.01 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Altimmune Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Altimmune Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.365 / 6.0486Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.